Spectral Medical Inc. EDTXF
0.70 USD +0.04 (+6.43%)
Nov 5, 2026, 3:02 PM EST
0.6999 Day range 0.6999
0.638 52-week range 1.10
- YTD
- -32.70%
- 1 year
- -30.70%
- Market cap
- 205.46M
- EPS (ttm)
- -0.09
- YTD return
- -32.70%
- 1-year return
- -30.70%
- Volume
- 1.00K
- Avg volume
- 9.85K
- Open
- 0.6999
- Previous close
- 0.6576
- Day's range
- 0.6999 – 0.6999
- 52-week range
- 0.638 – 1.10
2Y +0.2699 (+62.77%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | 0.00 | -0.03 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | -0.01 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -0.02 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.01 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.01 | — | — |
News
Spectral Medical Announces U.S. FDA Filing of PMA Application for PMX 
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders 
Spectral Medical Inc. (EDT:CA) Shareholder/Analyst Call Transcript 
Spectral Medical and Vantive Announce Topline 12 Month Follow-Up Results From Spectral's Tigris Trial 
Spectral Medical Announces PMA Submission to U.S. FDA for PMX 
Spectral Medical Announces First Quarter 2026 Financial Results and Provides Corporate Update 
Spectral Medical Inc. Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference 
Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update 
Spectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory Medicine 
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
Your note
Sign in to keep a note on EDTXF — it syncs with the Stock Master app.